Quality of life assessment and patient acceptability of intermittent versus continuous sex hormone suppression as treatment for locally advanced or metastatic prostatic cancer

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Plain English summary of protocol

Not provided at time of registration

Mr Timothy Philp
Scientific

Consultant Urologist
WXUHT
London
E11 1NR
United Kingdom

Primary study design	Interventional
Study design	Randomised controlled trial
Secondary study design	Randomised controlled trial
Scientific title
Study objectives	This study will investigate patient acceptance, quality of life and survival/disease progression free interval in patients with locally advanced or metastatic prostate cancer in remission after six months treatment and disease control with androgen blockade.
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Cancer: Prostate
Intervention	Intermittent vs continuous sex hormone suppression
Intervention type	Other
Primary outcome measure(s)	Patient acceptance, quality of life and survival/disease progression.
Key secondary outcome measure(s)	Not provided at time of registration
Completion date	31/12/2003

Participant type(s)	Patient
Age group	Not Specified
Sex	Male
Target sample size at registration	200
Key inclusion criteria	200 patients recruited from Urological Oncology Clinical who have had six months androgen blockade.
Key exclusion criteria	Not provided at time of registration
Date of first enrolment	31/12/1997
Date of final enrolment	31/12/2003

Consultant Urologist

London
E11 1NR
United Kingdom

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
IPD sharing plan

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2004		Yes	No